BioTech 365

OCTOBER 19, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Injured tumor cells activate immuno-oncology drugs to combat breast cancer and melanoma in mice.Injured tumor cells activate immuno-oncology drugs to combat breast cancer and melanoma in mice … Continue reading →

Drugs 40

Drugs Research 40

Pharma Times

MARCH 9, 2022

Trodelvy is accepted for use in mTNBC patients who have already received two or more systemic therapies

121

121

BioTech 365

FEBRUARY 11, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: AstraZeneca drops breast and prostate cancer programs in fourth quarter pipeline cull.AstraZeneca drops breast and prostate cancer programs in fourth quarter pipeline cull ntaylor Thu, 02/11/2021 – … Continue reading (..)

Research 40

Research 40

BioTech 365

JULY 21, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bayer’s drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice.Bayer’s drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice aliu Wed, … Continue reading (..)

Drugs 40

Drugs Research 40

BioTech 365

JUNE 17, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Targeting ‘enabler cells’ to stop the spread of triple-negative breast cancer.Targeting ‘enabler cells’ to stop the spread of triple-negative breast cancer aliu Thu, 06/17/2021 – 07:40 from … (..)

Research 40

Research 40

BioTech 365

JANUARY 21, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Veru touts novel breast cancer treatment strategy as drug nears phase 3.Veru

Drugs 40

Drugs Research 40

BioTech 365

OCTOBER 30, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: How understanding breast cancer heterogeneity could point to new drug targets.How understanding breast cancer heterogeneity could point to new drug targets arlene.weintraub Fri, 10/30/2020 – 09:20 from … Continue reading (..)

Drugs 40

Drugs Research 40

BioTech 365

OCTOBER 21, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Menarini, chased by 3 Big Pharmas, records win in breast cancer phase 3, plots path to FDA.Menarini, chased by 3 Big Pharmas, records win in breast cancer … Continue reading →

Research 40

Research 40

BioTech 365

APRIL 2, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Breast cancer studies pinpoint potential new drug targets to fight resistance.Breast cancer studies pinpoint potential new drug targets to fight resistance aliu Thu, 04/01/2021 – 07:52 from … Continue reading → (..)

Drugs 40

Drugs Research 40

BioTech 365

OCTOBER 1, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: A signaling chamber in tumors offers clues to fighting breast cancer metastasis.A

Research 40

Research 40

BioTech 365

SEPTEMBER 14, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Merck to pay Seattle Genetics $1.6B to ally on breast cancer ADC.Merck to pay Seattle Genetics $1.6B to ally on breast cancer ADC ntaylor Mon, 09/14/2020 – … Continue reading →

Genetics 40

Genetics Research 40

BioTech 365

APRIL 22, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: How a novel drug from a medicinal shrub blocks a previously ‘undruggable’ breast cancer target.How a novel drug from a medicinal shrub blocks a previously ‘undruggable’ breast … Continue reading →

Medicine 40

Medicine Drugs Research 40

BioTech 365

OCTOBER 19, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Breast cancer study uncovers new RNA targets for treatment and diagnostics.Breast cancer study uncovers new RNA targets for treatment and diagnostics arlene.weintraub Mon, 10/19/2020 – 08:41 from … Continue reading (..)

RNA 40

RNA Research 40

BioTech 365

MAY 8, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Daiichi Sankyo, AstraZeneca’s $5B Enhertu follow-up shows early signs of success in breast cancer.Daiichi Sankyo, AstraZeneca’s $5B Enhertu follow-up shows early signs of success in breast cancer … Continue reading (..)

Research 40

Research 40

BioTech 365

OCTOBER 24, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor.KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with … Continue reading →

Research 40

Research 40

BioTech 365

JANUARY 4, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Putting the ‘STING’ on CAR-T cells to turn them against breast cancer and other solid tumors.Putting the ‘STING’ on CAR-T cells to turn them against breast cancer … Continue reading →

Research 40

Research 40

Drug Discovery World

MARCH 14, 2023

Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep – forming incurable secondary tumours. This exciting discovery brings us a step closer to understanding how we can slow down or stop the development of ER+ secondary breast cancer in the lung.

Research 98

Research Drugs Protein Scientist 98

Pharmaceutical Technology

SEPTEMBER 26, 2022

The UK National Institute for Health and Care Excellence (NICE) has granted approval for Pfizer ’s palbociclib (Ibrance) in combination with anti-cancer therapy, fulvestrant, to treat advanced breast cancer patients. It acts by hindering proteins in cancer cells to avert cell division and growth.

HR 130

HR Drugs Hormones Medicine 130

pharmaphorum

FEBRUARY 21, 2022

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potentially making it an option for a much broader group of patients.

Trials 129

Trials Sales Hormones Drugs 129

Drug Discovery World

DECEMBER 22, 2023

News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer.

Drugs 52

Drugs Antibody FDA Approval Clinical Trials 52

Drug Discovery World

JANUARY 26, 2024

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal, pancreatic and lung cancer and leukaemia.

Drugs 52

Drugs Trials Research Development 52

World of DTC Marketing

FEBRUARY 17, 2022

The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. cost approximately $156.2

Medicine 271

Medicine Drugs Research Marketing 271

Drug Discovery World

MARCH 29, 2024

News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. Research uncovers how to target dormant breast cancer cells Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat.

Drugs 52

Drugs FDA Approval Antibody Trials 52

Drug Discovery World

SEPTEMBER 1, 2023

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. FDA fast-tracks monoclonal antibody for head and neck cancer Fast Track designation from the Food and Drug Administration (FDA) will accelerate the path to US submission for Alentis Therapeutics’ investigational monoclonal antibody.

Drugs 59

Drugs Antibody Clinical Trials Clinical Trials 59

Drug Discovery World

DECEMBER 27, 2023

There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer.

FDA Approval 52

FDA Approval Antibody Drugs Trials 52

XTalks

JUNE 30, 2023

This approval distinguishes Ultravist as the singular contrast agent in the US specifically indicated for visualizing confirmed or suspected breast lesions in adults in conjunction with mammography and/or ultrasound. Konstanze Diefenbach, head of Radiology Research and Development at Bayer, in the company’s news release. “We

FDA Approval 98

FDA Approval Radiology Trials Life Science 98

World of DTC Marketing

JANUARY 4, 2022

(Stat News) Today, a study followed 380 patients being treated at community oncology groups across the U.S. after they were diagnosed with metastatic colon cancer. Patients who experience financial hardship during cancer treatment are at higher risk for treatment nonadherence, poor quality of life, and worse survival.

Pharma Companies 273

Pharma Companies Drugs Medicine Research 273

pharmaphorum

SEPTEMBER 9, 2022

Prospects for Gilead Sciences’ Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury is still out on what that might mean for the drug commercially.

HR 52

HR Hormones Trials Sales 52

Drug Discovery World

MARCH 24, 2023

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in blood cancers, which could have huge implications for cancer treatment.

Drugs 52

Drugs Hormones Trials Research 52

Drug Discovery World

OCTOBER 7, 2022

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery.

Research 52

Research Immune Response Gene Bioinformatics 52

Drug Discovery World

NOVEMBER 10, 2023

News round-up for 6-10 November by DDW Digital Content Editor Diana Spencer. With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is my round-up focus again.

Drugs 52

Drugs Genome Genomics Research 52

Drug Discovery World

FEBRUARY 3, 2023

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer. As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. The post This week in drug discovery (30 January – 3 February) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs FDA Approval Development Manufacturing 52

Drug Discovery World

MARCH 17, 2023

News round-up for 13-17 March by DDW Digital Content Editor Diana Spencer. Artificial sweetener dampened T cell response in mice Scientists at the Francis Crick Institute have found that high consumption of a common artificial sweetener, sucralose, lowers activation of T cells in mice.

Bacteria 52

Bacteria Drugs Scientist Vaccination 52

Drug Discovery World

DECEMBER 27, 2023

There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer.

FDA Approval 52

FDA Approval Antibody Drugs Trials 52

pharmaphorum

MARCH 9, 2022

There isn’t enough evidence to support the use of Merck & Co/MSD’s Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the UK cost effectiveness watchdog NICE. Its long-term benefits are uncertain.

Drugs 73

Drugs Marketing 73

Drug Discovery World

JANUARY 23, 2024

Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The positive news is there has been an increase in trial recruitment across all the top five indications in 2023. Read the full report.

Research 52

Research Clinical Trials Clinical Trials Trials 52

pharmaphorum

APRIL 25, 2022

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging oral selective oestrogen receptor degrader (SERD) class. The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4

Trials 67

Trials Hormones HR Sales 67